New Advances in Cell and Gene Therapy Manufacturing: Ori Biotech’s IRO Platform Revealed

Introduction to Ori Biotech's IRO Platform

On May 29, 2024, Ori Biotech Ltd., a leader in cell and gene therapy (CGT) manufacturing technology, unveiled their latest innovation, the IRO® platform, at the International Society for Cell & Gene Therapy's 30th annual conference in Vancouver, British Columbia. This groundbreaking platform aims to overcome existing hurdles in CGT manufacturing.

The Need for Better Manufacturing Solutions

Cell and gene therapies have the potential to revolutionize medicine, but manufacturing challenges limit their accessibility. It is estimated that over 95% of patients do not have access to these treatments. Ori Biotech's IRO platform is designed to make these life-saving therapies more widely available.

Key Features of the IRO Platform

The IRO platform combines flexibility for early process development with the ability to scale into Good Manufacturing Practices (GMP). This seamless transition from research and development to GMP is facilitated by using the same instruments and consumables throughout the process.

Among its capabilities, IRO can automate and digitize labor-intensive workflows, reduce labor by up to 70%, cut the cost of goods by up to 50%, and significantly shorten processing and tech transfer times.

Technology Benefits and Impact

By automating key steps and reducing time and cost, the IRO platform promises to streamline the development of cell and gene therapies. This not only enhances therapy efficiency but also ensures higher throughput and better quality.

Jason C. Foster, CEO of Ori Biotech, emphasized the importance of making new therapies accessible and affordable to truly benefit patients. The company's focus on generating high-quality biological data from various cell types and protocols underlines the platform's reliability.

Empowering Scientists and Innovators

The IRO platform empowers scientists with the flexibility to optimize their processes. By standardizing and digitizing workflows, it allows them to focus on innovative solutions rather than manual, labor-intensive tasks.

According to Farlan Veraitch, PhD, Founder and CSO of Ori Biotech, IRO's development originated from a desire to support the scientific community in shortening the development timeline of cell therapies, thus increasing patient access.

Moving Forward with IRO

Ori Biotech invites industry stakeholders and peers to explore IRO’s capabilities. With its potential to transform CGT manufacturing, IRO is set to play a critical role in the next generation of medical treatments.

About Ori Biotech

Ori Biotech is based in London and Philadelphia and specializes in manufacturing technology aimed at expanding access to cell and gene therapies. Their IRO platform integrates hardware, software, consumables, and data analytics to enhance manufacturing efficiency and quality.

For more details, visit their website at oribiotech.com.